Samsung Bioepis And C-Bridge Capital To Develop And Commercialize Next-Generation Biosimilars In China
INCHEON, Korea, Feb 11 (Bernama-BUSINESS WIRE) — Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS® (ranibizumab) and SOLIRIS® (eculizumab), respectively, as well as SB3,…

